AMG 811

DRUG2 trials

Sponsors

Amgen

Conditions

NephritisSystemic Lupus Erythematosus

Phase 1

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

CompletedNCT00818948

AmgenNephritis, Systemic Lupus Erythematosus

Start: 2009-03-31End: 2014-08-31Updated: 2014-09-15

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

CompletedNCT02291588

AmgenSystemic Lupus Erythematosus

Start: 2007-12-31End: 2010-06-30Updated: 2014-11-14

Related Papers

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis

Lupus Science & Medicine2017-09-0164 citations